Abecassis Michael M's Form 4 filing
PharmaCyte Biotech, Inc. (PMCB) · filed Apr 2, 2026
- Accession no.
- 0001683168-26-002630
- Filed
- Apr 2, 2026
- Trade date
- Mar 31, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 derivative transaction. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001683168-26-005621 (Jul 17, 2026). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Abecassis Michael MCIK 0001879281 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Common Stock | AGrant or awardAcquired | +119,170 | $0.00 | $0 | 119,170 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Exhibit 24.1 - Power of Attorney